BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37142453)

  • 21. NTRK fusions and Trk proteins: what are they and how to test for them.
    Weiss LM; Funari VA
    Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
    Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
    Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer.
    Wu S; Liu Y; Li K; Liang Z; Zeng X
    J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
    Aref-Eshghi E; Lin F; Li MM; Zhong Y
    Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
    Yin MZ; Ma J; He Q; Shen P; Chen JF; Jin XT; Zhang ZD; Kuick CH; Chen HY; Ng EHQ; Aw SJ; Chang KTE
    Zhonghua Bing Li Xue Za Zhi; 2020 Jul; 49(7):675-680. PubMed ID: 32610377
    [No Abstract]   [Full Text] [Related]  

  • 26. NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China.
    Yin L; Shi C; He X; Qiu Y; Chen H; Chen M; Zhang Z; Chen Y; Zhou Y; Zhang H
    Pathology; 2023 Apr; 55(3):362-374. PubMed ID: 36641377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colonic Adenocarcinomas Harboring NTRK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 16 Cases and Review of the Literature.
    Lasota J; Chłopek M; Lamoureux J; Christiansen J; Kowalik A; Wasąg B; Felisiak-Gołąbek A; Agaimy A; Biernat W; Canzonieri V; Centonze G; Chmielik E; Daum O; Dubová M; Dziuba I; Goertz S; Góźdź S; Guttmejer-Nasierowska A; Haglund C; Hałoń A; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kaczorowski M; Kita P; Kołos M; Kopczyński J; Michal M; Milione M; Okoń K; Pęksa R; Pyzlak M; Ristimäki A; Ryś J; Szostak B; Szpor J; Szumiło J; Teresiński L; Waloszczyk P; Wejman J; Wesołowski W; Miettinen M
    Am J Surg Pathol; 2020 Feb; 44(2):162-173. PubMed ID: 31567189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of cancers with NTRK gene fusions.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
    Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
    Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
    Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ; Lee YH; Jin YT; Hsieh MS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer.
    Conde E; Hernandez S; Sanchez E; Regojo RM; Camacho C; Alonso M; Martinez R; Lopez-Rios F
    Arch Pathol Lab Med; 2021 Aug; 145(8):1031-1040. PubMed ID: 33112951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
    Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
    Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GISTs with
    Cao Z; Li J; Sun L; Xu Z; Ke Y; Shao B; Guo Y; Sun Y
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.